BioSpace
U.K.-based Exogene, which is developing novel T-cell receptor-based cell therapies, secured $2 million in new funding to help advance the development of its artificial intelligence (AI) platform for T-cell receptor discovery.
BioSpace
U.K.-based Exogene, which is developing novel T-cell receptor-based cell therapies, secured $2 million in new funding to help advance the development of its artificial intelligence (AI) platform for T-cell receptor discovery.